Lantheus Holdings, Inc. filed a Form 4 with the SEC on September 3, 2026, disclosing the sale of common stock in Perspective Therapeutics, Inc. (NASDAQ:CATX) on September 1, 2026.

Key Highlights

  • Shares sold: 35,769 shares of Perspective Therapeutics common stock were disposed of on September 1, 2026.
  • Weighted average price: The reported sale price was $3.1193 per share, a weighted average across multiple transactions.
  • Price range: Individual transactions occurred at prices ranging from $3.08 to $3.165, inclusive.
  • Remaining ownership: Following the transaction, 11,563,425 shares of common stock are beneficially owned, held directly by Lantheus Alpha Therapy, LLC.
  • Reporting relationship: Lantheus Holdings, Inc. is identified as a 10% owner of Perspective Therapeutics, Inc.
  • Holding structure: The shares are directly held by Lantheus Alpha Therapy, LLC, a wholly owned indirect subsidiary of Lantheus Holdings, Inc.

Lantheus Holdings Reduces Stake in Perspective Therapeutics via Open-Market Sales

According to the filing, Lantheus Holdings, Inc. reported the disposal of 35,769 shares of Perspective Therapeutics, Inc. common stock on September 1, 2026, using transaction code "S," indicating an open-market sale. The reported price of $3.1193 per share is a weighted average, as the shares were sold across multiple transactions at prices ranging from $3.08 to $3.165, inclusive. The filing states that full information on the number of shares sold at each separate price is available upon request to Perspective Therapeutics, any security holder, or the SEC staff.

The filing identifies Lantheus Holdings, Inc. as a 10% owner of Perspective Therapeutics, Inc. The shares involved are directly held by Lantheus Alpha Therapy, LLC, described in the filing as "a wholly owned indirect subsidiary of Lantheus Holdings, Inc." The filing notes that under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus Alpha Therapy, LLC, which holds direct beneficial ownership. Following the reported transaction, 11,563,425 shares remain beneficially owned on a direct basis by Lantheus Alpha Therapy, LLC.

The Form 4 was signed by Eric M. Green, identified as Vice President, Deputy General Counsel and Assistant Corporate Secretary, and was filed on September 3, 2026. The filing does not indicate the transaction was made pursuant to a Rule 10b5-1(c) plan, as that checkbox was not selected.

What Was Disclosed

Lantheus Holdings, Inc. disclosed a September 1, 2026 sale of 35,769 Perspective Therapeutics common shares at a weighted average price of $3.1193, leaving 11,563,425 shares beneficially owned through its indirect subsidiary, Lantheus Alpha Therapy, LLC.